Question: 230-word answers for both questions Do not use the same answers from the other post regarding this case study On December 27, 2001, Martha Stewarts
230-word answers for both questions
Do not use the same answers from the other post regarding this case study
On December 27, 2001, Martha Stewarts stockbroker, Peter Bacanovic, informed Stewart that two of his clients, Samuel Waksal, CEO of the biopharmaceutical company ImClone, and Waksals daughter, had just sold all of their ImClone stock. Waksal secretly knew that the FDA was about to reject Erbitux, a key cancer drug ImClone had developed. Stewart did not know about the impending FDA rejection of Erbitux, and information about Waksals sale of ImClones stock was not available to the public. After receiving the information about Waksals transaction, Stewart instructed her broker to sell all of her shares of ImClone stock. The following day, the FDA announced its rejection of Erbitux, and ImClones stock price plummeted 16 percent. Stewarts timely trade allowed her to avoid a $45,673 loss.
Eighteen months later, the Securities and Exchange Commission (SEC) filed charges against Stewart and her broker for illegal insider trading and securities fraud.1
Q1 Did Martha Stewart violate federal securities law? Why or why not?
Q2 Did Martha Stewarts broker violate securities law? Why or why not?
Step by Step Solution
There are 3 Steps involved in it
Get step-by-step solutions from verified subject matter experts
